#United States #South San Francisco #Michael J. Fox Foundation #Phylo #Target Atlas

Phylo Introduces Target Atlas

In a groundbreaking move, Phylo has launched Target Atlas, an innovative application aimed at revolutionizing the target prioritization process within drug discovery. This app is designed to assist researchers by drastically reducing the time required for evidence gathering—from months to mere days—enabling teams to focus on what really matters: developing effective therapies.

The Power of AI in Drug Discovery

Built on Biomni Lab, Phylo's Integrated Biology Environment, Target Atlas utilizes advanced AI agents that curate and synthesize evidence from extensive datasets, pulling insights from thousands of target-disease assessments. This technology offers a shared record that links findings back to their sources, ensuring that updates can be made seamlessly as new research comes to light. By harnessing the power of AI, Target Atlas enables scientists to focus on evaluating the quality and relevance of evidence rather than spending countless hours on data collection.

The Michael J. Fox Foundation Collaboration

One exciting facet of Target Atlas is its partnership with The Michael J. Fox Foundation for Parkinson's Research, which has worked with Phylo to create a specialized version for Parkinson’s disease. This version is part of the foundation's Targets to Therapies Initiative, designed to accelerate the pace at which effective therapies can be developed.

According to Gaia Skibinski, VP at The Michael J. Fox Foundation, “Expanding the number of well-characterized, druggable targets is a critical part of the puzzle. Tools like Phylo's Target Atlas can significantly enhance our research capabilities and help bring promising targets closer to viable therapies.”

Transforming the Target Selection Process

The drug development landscape is notoriously challenging, with only about 10% of drug programs advancing to approval. One of the critical phases in this process is the early target selection, which can be one of the least expensive points to influence project outcomes, yet carries significant risks if made improperly. Target Atlas aims to alleviate this by consolidating fragmented evidence from various fields—genetics, clinical activity, safety, and more—into a cohesive resource. This integrated approach allows researchers to make informed decisions based on comprehensive data, thus improving their chances of clinical success.

Enhanced Collaboration and Decision-Making

Target Atlas facilitates collaboration amongst teams by providing a shared, source-linked view that makes comparing evidence straightforward. Researchers can explore the evidence behind each target using dynamic 2x2 plots, enhancing transparency and alignment within teams. Furthermore, team leaders can adjust weightings according to their own evaluative criteria, observing how these changes shift rankings and interpretations of the data.

Accessible and Future-Oriented

The public edition of Target Atlas is available freely to anyone with a Biomni account, offering access to thousands of target-disease assessments and interactive visualizations. Additionally, for organizations seeking a more governed deployment, an enterprise edition is offered that accommodates extensive features such as proprietary data integration and AI-driven scoring.

As part of their forward-looking strategy, Phylo is reaching out to foundations, consortia, and patient organizations to further expand Target Atlas across other diseases, ultimately broadening its impact on the biopharmaceutical landscape.

In conclusion, with the launch of Target Atlas, Phylo is setting a new standard in target prioritization, paving the way for more effective therapies and showcasing the tremendous potential of AI in transforming the drug discovery process. To explore this tool, interested parties can visit Target Atlas or contact Phylo for inquiries regarding enterprise demonstrations and disease-specific sponsorship opportunities.